Judith Agudo

Has grant

Associate Professor

Dana-Farber Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Judith Agudo is an Assistant Professor at Dana Farber Cancer Institute in the United States. Her research focuses on metastatic colonization and the mechanisms through which cancer cells escape immune surveillance. Her recent work contributes to a deeper understanding of tumor biology and therapeutic strategies.

Recent Grants

Grant: Close

Deciphering obesity-mediated immune evasion mechanisms in colorectal tumorigenesis

Open Date: 2018-04-01

Close Date: 2019-03-01

Grant: Close

Role of the transcription factor KLF4 in immune evasion of skin stem cells and cancer stem cells

Open Date: 2018-01-01

Close Date: 2019-01-01

Grant: Close

Novel strategy for induction of tolerance in mouse models of T1D

Open Date: 2013-03-01

Close Date: 2016-02-01

Articles (6)

High-grade serous ovarian cancer (HGSOC) originates from fallopian tube (FT) precursors. However, the molecular changes that occur as precancerous lesions progress to HGSOC are not well understood. To address this, we integrated high-plex imaging and spatial transcriptomics to analyze human tissue samples at different stages of HGSOC development, including p53 signatures, serous tubal intraepithelial carcinomas (STIC), and invasive HGSOC. Our findings reveal immune modulating mechanisms within precursor epithelium, characterized by chromosomal instability, persistent IFN signaling, and dysregulated innate and adaptive immunity. FT precursors display elevated expression of MHC class I, including HLA-E, and IFN-stimulated genes, typically linked to later-stage tumorigenesis. These molecular alterations coincide with progressive shifts in the tumor microenvironment, transitioning from immune surveillance in early STICs to immune suppression in advanced STICs and cancer. These insights identify potential biomarkers and therapeutic targets for HGSOC interception and clarify the molecular transitions from precancer to cancer. Significance: This study maps the immune response in FT precursors of HGSOC, highlighting localized IFN signaling, chromosomal instability, and competing immune surveillance and suppression along the progression axis. It provides an explorable public spatial profiling atlas for investigating precancer mechanisms, biomarkers, and early detection and interception strategies. See related commentary by Recouvreux and Orsulic, p. 1093

Year:

2025

This SupplementaryTable S8 is the normalized count matrix File for GeoMx data for the manuscript: Kader, Lin, Hug and colleagues titled "Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma". https://zenodo.org/records/14502077

Year:

2025

Immunotherapies have yet to demonstrate significant efficacy in the treatment of hormone receptor–positive (HR + ) breast cancer. Given that endocrine therapy (ET) is the primary approach for treating HR + breast cancer, we investigated the effects of ET on the tumor immune microenvironment (TME) in HR + breast cancer. Spatial proteomics of primary HR + breast cancer samples obtained at baseline and after ET from patients enrolled in a neoadjuvant clinical trial (NCT02764541) indicated that ET upregulated β2-microglobulin and influenced the TME in a manner that promotes enhanced immunogenicity. To gain a deeper understanding of the underlying mechanisms, the intrinsic effects of ET on cancer cells were explored, which revealed that ET plays a crucial role in facilitating the chromatin binding of RelA, a key component of the NF-κB complex. Consequently, heightened NF-κB signaling enhanced the response to interferon-gamma, leading to the upregulation of β2-microglobulin and other antigen presentation-related genes. Further, modulation of NF-κB signaling using a SMAC mimetic in conjunction with ET augmented T-cell migration and enhanced MHC-I-specific T-cell–mediated cytotoxicity. Remarkably, the combination of ET and SMAC mimetics, which also blocks prosurvival effects of NF-κB signaling through the degradation of inhibitors of apoptosis proteins, elicited tumor regression through cell autonomous mechanisms, providing additional support for their combined use in HR + breast cancer. Significance: Adding SMAC mimetics to endocrine therapy enhances tumor regression in a cell autonomous manner while increasing tumor immunogenicity, indicating that this combination could be an effective treatment for HR + patients with breast cancer.

Year:

2025

High-Grade Serous Ovarian Cancer (HGSOC) originates from fallopian tube (FT) precursors. However, the molecular changes that occur as precancerous lesions progress to HGSOC are not well understood. To address this, we integrated high-plex imaging and spatial transcriptomics to analyze human tissue samples at different stages of HGSOC development, including p53 signatures, serous tubal intraepithelial carcinomas (STIC), and invasive HGSOC. Our findings reveal immune modulating mechanisms within precursor epithelium, characterized by chromosomal instability, persistent interferon (IFN) signaling, and dysregulated innate and adaptive immunity. FT precursors display elevated expression of MHC-class I, including HLA-E, and IFN-stimulated genes, typically linked to later-stage tumorigenesis. These molecular alterations coincide with progressive shifts in the tumor microenvironment, transitioning from immune surveillance in early STICs to immune suppression in advanced STICs and cancer. These insights identify potential biomarkers and therapeutic targets for HGSOC interception and clarify the molecular transitions from precancer to cancer. STATEMENT OF SIGNIFICANCE This study maps the immune response in fallopian tube precursors of high-grade serous ovarian cancer, highlighting localized interferon signaling, CIN, and competing immune surveillance and suppression along the progression axis. It provides an explorable public spatial profiling atlas for investigating precancer mechanisms, biomarkers, and early detection and interception strategies.

Year:

2024

Immunotherapies have yet to demonstrate significant efficacy in the treatment of hormone receptor positive (HR+) breast cancer. Given that endocrine therapy (ET) is the primary approach for treating HR+ breast cancer, we investigated the effects of ET on the tumor immune microenvironment (TME) in HR+ breast cancer. Spatial proteomics analysis of primary HR+ breast cancer samples obtained at baseline and after ET from patients enrolled in a neoadjuvant clinical trial (NCT02764541) indicated that ET upregulated B2-microglobulin and influenced the TME in a manner that promotes enhanced immunogenicity. To gain a deeper understanding of the underlying mechanisms, the intrinsic effects of ET on cancer cells were explored, which revealed that ET plays a crucial role in facilitating the chromatin binding of RelA, a key component of the NF-κB complex. Consequently, heightened NF-κB signaling enhanced the response to interferon-gamma, leading to the upregulation of β2-microglobulin and other antigen presentation-related genes. Further, modulation of NF-κB signaling using a SMAC-mimetic in conjunction with ET augmented T-cell migration and enhanced MHC-I specific T-cell mediated cytotoxicity. Remarkably, the combination of ET and SMAC-mimetics, which also block pro-survival effects of NF-κB signaling through the degradation of inhibitors of apoptosis (IAP) proteins, elicited tumor regression through cell-autonomous mechanisms, providing additional support for their combined use in HR+ breast cancer.

Year:

2024

Year:

2020

Collaborators (13)

Sandro Santagata

Brigham and Women's Hospital

UNITED STATES
View details

Francisco Hermida-Prado

Principal Investigator

University of Oviedo

SPAIN
View details

Baby Satravada

Bioinfo.Software Engr I

Sloan Kettering Institute

UNITED STATES
View details

Eugene Schuster

Institute of Cancer Research

UNITED KINGDOM
View details

W. Fraser Symmans

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alana Welm

Chair

Huntsman Cancer Institute

UNITED STATES
View details

Peter Sorger

Otto Krayer Professor of Systems Pharmacology

Harvard Medical School

UNITED STATES
View details

Juana M. García-Pedrero

Principal Investigator

University of Oviedo

SPAIN
View details

Elizabeth Mittendorf

Harvard University

UNITED STATES
View details

Tanjina Kader

Lab Head/Senior Lecturer

MONASH UNIVERSITY

AUSTRALIA
View details

Ronny Drapkin

Franklin Payne Professor of Pathology in Obstetrics and Gynecology

University of Pennsylvania

UNITED STATES
View details

James Heath

Professor

Institute for Systems Biology

UNITED STATES
View details

Jeremy Muhlich

Massachusetts Institute of Technology

UNITED STATES
View details